IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington
Retrieved on:
Tuesday, March 19, 2024
LOS ANGELES, March 19, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN , a multifaceted communications organization engaged in connecting public companies with the investment community, today announces that Rob Etherington, President, Director and CEO of late clinical-stage biopharmaceutical company Clene Inc. (NASDAQ: CLNN) , recently appeared on First in Human, a biotech-focused podcast featuring interviews with industry leaders and investors to learn about their journeys to in-human clinical trials.
Key Points:
- LOS ANGELES, March 19, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN , a multifaceted communications organization engaged in connecting public companies with the investment community, today announces that Rob Etherington, President, Director and CEO of late clinical-stage biopharmaceutical company Clene Inc. (NASDAQ: CLNN) , recently appeared on First in Human, a biotech-focused podcast featuring interviews with industry leaders and investors to learn about their journeys to in-human clinical trials.
- During the interview, Etherington highlighted information about Clene’s work in the field of nanotechnology.
- “For decades…the idea of a therapeutic elemental metal having some medicinal efficacy has been well understood.
- We then proceeded into two amyotrophic lateral sclerosis (ALS) studies and one multiple sclerosis study, all of which have concluded in the past 18 months.